Literature DB >> 1407576

Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin's disease.

J Hammack1, H Kotanides, M K Rosenblum, J B Posner.   

Abstract

We reviewed clinical findings and serologic data on 18 men and three women with paraneoplastic cerebellar degeneration (PCD) associated with Hodgkin's disease (HD). The patients were 20 to 77 years old (median, 44). The lymphoma preceded neurologic symptoms by 1 to 54 months in 17/21 patients, but stage or activity did not correlate with severity of neurologic disease; six developed PCD while in HD remission. PCD evolved subacutely (over weeks to months) and was pancerebellar in most. Ten had downbeat nystagmus. Thirteen stabilized in a disabled state (wheelchair- or bed-bound), five stabilized ambulatory, and three, who had progressed to a nonambulatory state, recovered. The clinical findings were usually only cerebellar but one patient had an encephalopathy, three long-tract signs, and two sensory neuropathy. Plasmapheresis (seven patients) and corticosteroids or other immunosuppressant medication (eight patients) did not help; one improved dramatically after treatment with clonazepam. Two patients improved spontaneously. Six patients had serum antibodies that reacted specifically with Purkinje cells. The pattern was distinct from that of PCD with gynecologic cancer (anti-Yo) or small-cell lung cancer (anti-Hu). Western blotting failed to identify a discrete Purkinje cell antigen. Seropositive patients did not differ clinically from their seronegative counterparts. HD-associated PCD is more common in men and in a younger age group than in PCD with other malignancies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1407576     DOI: 10.1212/wnl.42.10.1938

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  21 in total

Review 1.  A review of the therapy of paraneoplastic neurologic syndromes.

Authors:  A Das; F H Hochberg; S McNelis
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

Review 2.  Recognizing unusual manifestations of Hodgkin lymphoma.

Authors:  Nicholas A Barber; Philip J Bierman
Journal:  Curr Hematol Malig Rep       Date:  2012-09       Impact factor: 3.952

3.  Central nervous system angiitis in Hodgkin's disease.

Authors:  Andrea Morotti; Michele Malagola; Valeria Cancelli; Enza Gatti; Maria Codella; Renata Rao; Alessandro Pezzini; Roberto Gasparotti; Domenico Russo; Alessandro Padovani
Journal:  J Neurol       Date:  2013-10-18       Impact factor: 4.849

Review 4.  Neurological paraneoplastic syndromes.

Authors:  J Dalmau; J B Posner
Journal:  Springer Semin Immunopathol       Date:  1996

5.  Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.

Authors:  M J Titulaer; R Soffietti; J Dalmau; N E Gilhus; B Giometto; F Graus; W Grisold; J Honnorat; P A E Sillevis Smitt; R Tanasescu; C A Vedeler; R Voltz; J J G M Verschuuren
Journal:  Eur J Neurol       Date:  2010-09-29       Impact factor: 6.089

6.  Treatment of paraneoplastic neurologic disorders.

Authors:  John E Greenlee
Journal:  Curr Treat Options Neurol       Date:  2010-05       Impact factor: 3.598

7.  Antibodies to Delta/notch-like epidermal growth factor-related receptor in patients with anti-Tr, paraneoplastic cerebellar degeneration, and Hodgkin lymphoma.

Authors:  Maxwell Greene; Yongjie Lai; Nicolle Baella; Josep Dalmau; Eric Lancaster
Journal:  JAMA Neurol       Date:  2014-08       Impact factor: 18.302

8.  Paraneoplastic cerebellar degeneration with a circulating antibody against neurons and non-neuronal cells.

Authors:  H Tomimoto; J M Brengman; T Yanagihara
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

Review 9.  Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.

Authors:  Mia Levite
Journal:  J Neural Transm (Vienna)       Date:  2014-08-01       Impact factor: 3.575

10.  Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes.

Authors:  J Honnorat; J C Antoine; E Derrington; M Aguera; M F Belin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-09       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.